Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in developing medicines for cancer and other serious diseases. In its transcriptional regulation program CYC065, Co.'s cyclin dependent kinase inhibitor, is being evaluated as a single agent and in combination with venetoclax in studies in patients with solid tumors and hematological malignancies. In its deoxyribonucleic acid damage response program Co. is evaluating sapacitabine in combination with venetoclax in studies in patients with hematological malignancies. In its anti-mitotic program, Co. is evaluating CYC140, a Polo-like Kinase inhibitor, in studies in patients with hematological malignancies. The CYCC stock yearly return is shown above.
The yearly return on the CYCC stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2014 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the CYCC annual return calculation with any dividends reinvested as applicable (on ex-dates).
|